新型微血管超声列线图预测慢性肾病肾纤维化
本研究纳入208例慢性肾病患者(训练组141例、外部验证组67例),均行肾超声与活检,按病理分为轻度与中重度纤维化。整合SRUS、SMI、RI及临床指标构建列线图。结果显示该列线图训练组AUC为0.944,外部验证组AUC为0.907,提示其可作为无创评估肾纤维化严重程度的方法。
要点
- 列线图结合SRUS、SMI、RI及高血压、BUN、eGFR可预测中重度肾纤维化。
- 训练组AUC 0.944,外部验证组AUC 0.907,预测效能较高。
- 该模型可用于慢性肾病肾纤维化风险分层,支持无创评估。
核心结论
- 该列线图整合SRUS、SMI、RI、高血压、BUN和eGFR,对慢性肾病中重度肾纤维化具有良好预测性能。
研究设计与样本
- 多中心研究,共纳入208例慢性肾病患者,训练组141例,外部验证组67例。
- 所有患者均接受肾脏超声检查及肾穿刺活检。
- 根据病理结果将患者分为轻度纤维化组与中重度纤维化组。
- 使用LASSO回归筛选候选预测因子,再行相关性及多重共线性分析,并用多变量logistic回归构建列线图。
- 模型性能通过ROC曲线、校准曲线及决策曲线分析进行评估。
诊断标准与关键数值
- 列线图包含变量为SRUS、SMI、RI、高血压、BUN和eGFR。
- 训练组列线图AUC为0.944(95%CI:0.908-0.981)。
- 外部验证组列线图AUC为0.907(95%CI:0.835-0.980)。
- 训练组校准截距为0.003,校准斜率为1.002。
- 外部验证组校准截距为-0.296,校准斜率为0.767。
临床应用与阅片要点
- 临床可联合SRUS、SMI、RI及eGFR等指标对慢性肾病患者进行肾纤维化风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop and validate a nomogram integrating ultrasound microvascular imaging (super-resolution ultrasound [SRUS], superb microvascular imaging [SMI]), resistive index (RI), and clinical features for the non-invasive assessment of renal fibrosis severity in chronic kidney disease (CKD).
MATERIALS AND METHODS: A total of 208 CKD patients (141 in the training cohort and 67 in the external validation cohort) were included in the study. All patients underwent renal ultrasound and biopsy. Based on the pathological findings, patients were classified into mild and moderate-to-severe fibrosis groups. Candidate predictors were selected using least absolute shrinkage and selection operator (LASSO) regression, followed by correlation and multicollinearity analysis. A multivariable logistic regression model was used to construct a nomogram. Model performance was evaluated by receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA).
RESULTS: The nomogram, incorporating SRUS, SMI, RI, hypertension, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR), showed good predictive performance. The area under the curve (AUC) for the nomogram was 0.944 (95% confidence interval [CI]: 0.908-0.981) in the training cohort and 0.907 (95% CI: 0.835-0.980) in the external validation cohort. Calibration analyses showed acceptable agreement between predicted and observed probabilities, with calibration intercepts/slopes of 0.003/1.002 in the training cohort and -0.296/0.767 in the external validation cohort.
CONCLUSION: This nomogram may provide a non-invasive approach for assessing renal fibrosis severity and supporting risk stratification in patients with CKD.
引用
- Zhang, Liang, Huang, et al. Multi-Institutional Development and Validation of a Nomogram Based on New Microvascular Ultrasound Techniques to Predict the Severity of Renal Fibrosis in Chronic Kidney Disease. J Ultrasound Med. 2026. PMID: 42550578. doi:10.1002/jum.70409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。